Increased platelet GSK3B activity in patients with mild cognitive impairment and Alzheimer's disease

Journal of Psychiatric Research

Volumn 45, Issue 2, 2011, Pages 220-224

  Forlenza, Orestes V ^a   Torres, Carolina A ^a   Talib, Leda L ^a   de Paula, Vanessa J ^a   Joaquim, Helena P G ^a   Diniz, Breno S ^a   Gattaz, Wagner F ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Alzheimer's disease; GSK3B; Mild cognitive impairment; Platelets

Indexed keywords

GLYCOGEN SYNTHASE KINASE 3BETA; SERINE;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; COMPARATIVE STUDY; CONTROL GROUP; CONTROLLED STUDY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEMORY; MILD COGNITIVE IMPAIRMENT; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; THROMBOCYTE ACTIVATION; WESTERN BLOTTING;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; ANALYSIS OF VARIANCE; BLOOD PLATELETS; COGNITION DISORDERS; FEMALE; GLYCOGEN SYNTHASE KINASE 3; HUMANS; MALE; MENTAL STATUS SCHEDULE; SERINE;

EID: 78650677040     PISSN: 00223956     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jpsychires.2010.06.002     Document Type: Article

References (41)

1. Balaraman Y., Limaye E.R., Levey A.I., Srinivasan S. Glycogen synthase kinase 3B and Alzheimer's disease: pathophysiological and therapeutic significance. Cellular and Molecular Life Science 2006, 63:1226-1235.
2. Barry F.A., Graham G.J., Fry M.J., Gibbins J.M. Regulation of glycogen synthase kinase 3 in humans platelets: a possible role in platelet function?. FEBS Letters 2003, 553:173-178.
3. Chin P.C., Majdzadeh N., D'Mello S.R. Inhibition of GSK3β is a common event in neuroprotection by different survival factors. Molecular Brain Research 2005, 137:193-201.
4. Di Luca M., Colciaghi F., Pastorino L., Borroni B., Padovani A., Cattabeni F. Platelets as a peripheral district were to study pathogenetic mechanisms of Alzheimer disease: the case of amyloid precursor protein. European Journal of Pharmacology 2000, 405:277-283.
5. Diniz B.S., Nunes P.V., Yassuda M.S., Pereira F.S., Flaks M.K., Viola L.F., et al. Mild cognitive impairment: cognitive screening or neuropsychological assessment?. Revista Brasileira de Psiquiatria 2008, 30:316-321.
6. Diniz B.S., Pinto Júnior J.A., Forlenza O.V. Do CSF total tau, phosphorylated tau, and beta-amyloid 42 help to predict progression of mild cognitive impairment to Alzheimer's disease? A systematic review and meta-analysis of the literature. World Journal of Biological Psychiatry 2008, 9:172-182.
7. Doble B.W., Woodgett J.R. GSK-3: tricks of the trade for a multi-tasking kinase. Journal of Cell Science 2003, 116:1175-1186.
8. Embi N., Rylatt D.B., Cohen P. Glycogen synthase kinase-3 from rabbit skeletal muscle. Separation from cyclic-AMP-dependent protein kinase and phosphorylase kinase. European Journal of Biochemistry 1980, 107:519-527.
9. Folstein M.F., Folstein S.E., Mchugh P.R. Mini-mental state: a practical method for grading the cognitive state of patients for the clinician. Journal of Psychiatric Research 1975, 12:189-198.
10. Forde J.E., Dale T.C. Glycogen synthase kinase 3: a key regulator of cell fate. Cellular and Molecular Life Science 2007, 64:1930-1944.
11. Forlenza O.V., Wacker P., Nunes P.V., Yacubian J., Castro C.C., Otaduy M.C.G., et al. Reduced phospholipid breakdown in Alzheimer's brains: a 31P spectroscopy study. Psychopharmacology 2005, 180:359-365.
12. Frame S., Cohen P. GSK3 takes centre stage more than 20 years after its discovery. The Biochemical Journal 2001, 359:1-16.
13. Gattaz W.F., Cairns N.J., Levy R., Förstl H., Braus D.F., Maras A. Decreased phospholipase A2 activity in the brain and in platelets of patients with Alzheimer's disease. European Archives of Psychiatry and Clinical Neuroscience 1996, 246:129-131.
14. 2 activity in Alzheimer's disease and mild cognitive impairment. Journal of Neural Transmission 2004, 111:591-601.
15. Gould T.D., Manji H.K. Glycogen synthase kinase-3: a putative molecular target for lithium mimetic drugs. Neuropsychopharmacology 2005, 30:1223-1237.
16. Grimes C.A., Jope R.S. The multifaceted roles of GSK3β in cellular signaling. Progress in Neurobiology 2001, 65:391-426.
17. Hooper C., Killick R., Lovestone S. The GSK3 hypothesis of Alzheimer's disease. Journal of Neurochemistry 2008, 104:1433-1439.
18. Hye A., Kerr F., Archer N., Foy C., Poppe M., Brown R., et al. Glycongen synthase kinase 3 is increased in white cells early in Alzheimer's Disease. Neuroscience Letters 2005, 373:1-4.
19. Jope R.S., Yuskaitis C.J., Beurel E. Glycogen synthase kinase-3 (GSK3): inflammation, diseases, and therapeutics. Neurochemistry Research 2007, 32:577-595.
20. Kar S., Slowikowski S.P.M., Westaway D., Mount H.T.J. Interactions between β amyloid and central cholinergic neurons: implications for Alzheimer's disease. Journal of Psychiatry and Neuroscience 2004, 29:427-441.
21. Klein P.S., Melton D.A. A molecular mechanism for the effect of lithium on development. Proceedings of the National Academy of Sciences of the United States of America 1996, 93:8455-8459.
22. Kessing L.V., Søndergård L., Forman J.L., Andersen P.K. Lithium treatment and risk of dementia. Archives of General Psychiatry 2008, 65:1331-1335.
23. Koh S., Noh M.Y., Kim S.Y. Amyloid-beta-induced neurotoxicity is reduced by inhibition of glycogen synthase kinase-3. Brain Research 2008, 1188:254-262.
24. Kozlovsky N., Amar S., Belmaker R.H., Agam G. Psychotropic drugs affect Ser9-phosphorylated GSK-3 beta protein levels in rodent frontal cortex. International Journal of Neuropsychopharmacology 2006, 9:337-342.
25. Lovestone S., Reynolds C.H., Latimer D., Davis D.R., Anderton B.H., Gallo J.M., et al. Alzheimer's disease-like phosphorylation of the microtubule-associated protein tau by glycogen synthase kinase-3 in transfected mammalian cells. Current Biology 1994, 4:1077-1086.
26. Lovestone S., McLoughlin D.M. Protein aggregates and dementia: is there a common toxicity?. Journal of Neurology Neurosurgery and Psychiatry 2002, 72:152-161.
27. Martinez A., Alonso M., Castro A., Perez C., Moreno F.J. First non-ATP competitive glycogen synthase kinase 3β (GSK-3β) inhibitors: thiadiazolidinones (TDZD) as potential drugs for the treatment of Alzheimer's disease. Journal of Medicinal Chemistry 2002, 45:1292-1299.
28. McKhann G., Drachman D., Folstein M., Katzman R., Price D., Stadlan E.M. Clinical diagnosis of Alzheimer disease: report of NINCDS-ADRDA work group under the auspices of Department of Health and Human Service Task Force on Alzheimer Disease. Neurology 1984, 34:939-944.
29. Mendes C.T., Mury F.B., Moreira E.S., Alberto F.L., Forlenza O.V., Dias-Neto E., et al. Lithium reduces Gsk3b mRNA levels: implications for Alzheimer disease. European Archives of Psychiatry and Clinical Neuroscience 2009, 259:16-22.
30. Mohammed El H., Rosado J.A. Platelet function in hypertension. Blood Cells, Molecules and Diseases 2009, 42:38-43.
31. Muyllaert D., Kremer A., Jaworski T., Borghgraef P., Devijver H., Croes S., et al. Glycogen synthase kinase-3β, or a link between amyloid and tau pathology?. Genes, Brain and Behavior 2008, 7:57-66.
32. Nunes P.V., Forlenza O.V., Gattaz W.F. Lithium and risk for Alzheimer's disease in elderly patients with bipolar disorder. British Journal of Psychiatry 2007, 190:359-360.
33. Nunes P.V., Diniz B.S., Radanovic M., Abreu I.D., Borelli D.T., Yassuda M.S., et al. CAMcog as a screening tool for diagnosis of mild cognitive impairment and dementia in a Brazilian clinical sample of moderate to high education. International Journal of Geriatric Psychiatry 2008, 23:1127-1133.
34. Noble W., Planel E., Zehr C., Olm V., Meyerson J., Suleman J., et al. Inhibition of glycogen synthase kinase-3 by lithium correlates with reduced tauopathy and degeneration in vivo. Proceedings of the National Academy of Sciences of the United States of America 2005, 102:6990-6995.
35. Padovani A., Pastorino L., Borroni B., Colciaghi F., Rozzini L., Monastero R., et al. Amyloid precursor protein in platelets. A peripheral marker for the diagnosis of sporadic AD. Neurology 2001, 57:2243-2248.
36. Peineau S., Bradley C., Taghibiglou C., Doherty A., Bortolotto Z.A., Wang Y.T., et al. The role of GSK-3 in synaptic plasticity. British Journal of Pharmacology 2008, 153:S428-S437.
37. Petersen R.C., Doody R., Kurz A., Mohs R.C., Morris J.C., Rabins P.V., et al. Current concepts in mild cognitive impairment. Archives of Neurology 2001, 58:1985-1992.
38. Planel E., Sun X., Takashima A. Role of GSK-3β in Alzheimer's disease pathology. Drug Development Research 2002, 56:491-510.
39. Rockenstein E., Torrance M., Adame A., Mante M., Bar-on P., Rose J.B., et al. Neuroprotective effects of regulators of the glycogen synthase kinase-3β signaling pathway in a transgenic model of Alzheimer's disease are associated with reduced amyloid precursor protein phosphorylation. Journal of Neuroscience 2007, 27:1981-1991.
40. Roth M., Tym E., Mountjoy C.Q., Huppert F.A., Hendrie H., Verma S., et al. A standardized instrument for the diagnosis of mental disorders in the elderly with special reference to early detection of dementia. British Journal of Psychiatry 1986, 149:698-709.
41. Zainaghi I.A., Forlenza O.V., Gattaz W.F. Abnormal APP processing in platelets of patients with Alzheimer's disease: correlations with membrane fluidity and cognitive decline. Psychopharmacology 2007, 192:547-553.